1. Home
  2. SSKN vs APLM Comparison

SSKN vs APLM Comparison

Compare SSKN & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SSKN
  • APLM
  • Stock Information
  • Founded
  • SSKN 1989
  • APLM 2016
  • Country
  • SSKN United States
  • APLM United States
  • Employees
  • SSKN N/A
  • APLM N/A
  • Industry
  • SSKN Medical/Dental Instruments
  • APLM Blank Checks
  • Sector
  • SSKN Health Care
  • APLM Finance
  • Exchange
  • SSKN Nasdaq
  • APLM Nasdaq
  • Market Cap
  • SSKN 12.3M
  • APLM 12.3M
  • IPO Year
  • SSKN 2005
  • APLM N/A
  • Fundamental
  • Price
  • SSKN $2.70
  • APLM $7.02
  • Analyst Decision
  • SSKN
  • APLM Strong Buy
  • Analyst Count
  • SSKN 0
  • APLM 2
  • Target Price
  • SSKN N/A
  • APLM $425.00
  • AVG Volume (30 Days)
  • SSKN 4.3K
  • APLM 7.4K
  • Earning Date
  • SSKN 03-26-2025
  • APLM 03-04-2025
  • Dividend Yield
  • SSKN N/A
  • APLM N/A
  • EPS Growth
  • SSKN N/A
  • APLM N/A
  • EPS
  • SSKN N/A
  • APLM N/A
  • Revenue
  • SSKN $32,674,999.00
  • APLM $2,101,000.00
  • Revenue This Year
  • SSKN $0.94
  • APLM N/A
  • Revenue Next Year
  • SSKN $11.30
  • APLM N/A
  • P/E Ratio
  • SSKN N/A
  • APLM N/A
  • Revenue Growth
  • SSKN N/A
  • APLM 70.54
  • 52 Week Low
  • SSKN $2.51
  • APLM $6.38
  • 52 Week High
  • SSKN $6.00
  • APLM $80.50
  • Technical
  • Relative Strength Index (RSI)
  • SSKN 43.38
  • APLM 37.88
  • Support Level
  • SSKN $2.65
  • APLM $6.70
  • Resistance Level
  • SSKN $2.89
  • APLM $7.60
  • Average True Range (ATR)
  • SSKN 0.13
  • APLM 0.70
  • MACD
  • SSKN 0.00
  • APLM -0.03
  • Stochastic Oscillator
  • SSKN 14.71
  • APLM 22.30

About SSKN Strata Skin Sciences Inc.

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Share on Social Networks: